Abstract
Cancer immunotherapy, a promising and widely applied mode of oncotherapy, makes use of immune stimulants and modulators to overcome the immune dysregulation present in cancer, and leverage the host’s immune capacity to eliminate tumors. Although some success has been seen in this field, toxicity and weak immune induction remain challenges. Liposomal nanosystems, previously used as targeting agents, are increasingly functioning as immunotherapeutic vehicles, with potential for delivery of contents, immune induction, and synergistic drug packaging. These systems are tailorable, multifunctional, and smart. Liposomes may deliver various immune reagents including cytokines, specific T-cell receptors, antibody fragments, and immune checkpoint inhibitors, and also present a promising platform upon which personalized medicine approaches can be built, especially with preclinical and clinical potentials of liposomes often being frustrated by inter-and intrapatient variation. In this review, we show the potential of liposomes in cancer immunotherapy, as well as the methods for synthesis and in vivo progression thereof. Both preclinical and clinical studies are included to comprehensively illuminate prospects and challenges for future research and application.
Original language | English |
---|---|
Article number | 26 |
Journal | Pharmaceutics |
Volume | 14 |
Issue number | 1 |
DOIs | |
Publication status | Published - 23 Dec 2021 |
Bibliographical note
Funding Information:This work is based on the research supported in part by the National Research Foundation of South Africa (Grant Number 129445), and the China Scholarship Council (File Number 202008310151).
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.